Do analysts rate ENTO or QLGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, ENTO or QLGN?

Entero Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entero Therapeutics N/A N/A -$18.06M -$1.69 N/A Qualigen Therapeutics N/A N/A -$6.26M -$7.50 N/A

Is ENTO or QLGN more profitable?

Qualigen Therapeutics' return on equity of 0.00% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -461.02% -14.72% Qualigen Therapeutics N/A N/A -202.16%

Do analysts recommend QLGN or BTCT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BTC Digital 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is QLGN or BTCT more profitable?

Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A N/A -202.16% BTC Digital N/A N/A N/A

Does the media refer more to QLGN or BTCT?

In the previous week, BTC Digital had 5 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 6 mentions for BTC Digital and 1 mentions for Qualigen Therapeutics. BTC Digital's average media sentiment score of 0.24 beat Qualigen Therapeutics' score of 0.00 indicating that BTC Digital is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BTC Digital 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend QLGN or CSAI?

Cloudastructure has a consensus target price of $45.00, indicating a potential upside of 750.66%. Given Cloudastructure's stronger consensus rating and higher probable upside, analysts clearly believe Cloudastructure is more favorable than Qualigen Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cloudastructure 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer QLGN or CSAI?

In the previous week, Cloudastructure had 2 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 3 mentions for Cloudastructure and 1 mentions for Qualigen Therapeutics. Cloudastructure's average media sentiment score of 0.92 beat Qualigen Therapeutics' score of 0.00 indicating that Cloudastructure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qualigen Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cloudastructure 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate HTCR or QLGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HeartCore Enterprises 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate ALBT or QLGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalon GloboCare 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ALBT or QLGN more profitable?

Company Net Margins Return on Equity Return on Assets Avalon GloboCare N/A N/A -74.36% Qualigen Therapeutics N/A N/A -202.16%

Qualigen Therapeutics (QLGN) Competitors

$1.12 -0.06 (-4.68%)

As of 08/21/2026

Compare

QLGN vs. ENTO, BTCT, CSAI, HTCR, and ALBT

Should you buy Qualigen Therapeutics stock or one of its competitors? Qualigen Therapeutics's main competitors and comparable companies include Entero Therapeutics (ENTO), BTC Digital (BTCT), Cloudastructure (CSAI), HeartCore Enterprises (HTCR), and Avalon GloboCare (ALBT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Qualigen Therapeutics compare to Entero Therapeutics?

Entero Therapeutics (NASDAQ:ENTO) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Qualigen Therapeutics' return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-461.02%	-14.72%
Qualigen Therapeutics	N/A	N/A	-202.16%

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Entero Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	N/A	N/A	-$18.06M	-$1.69	N/A
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A

In the previous week, Qualigen Therapeutics had 1 more articles in the media than Entero Therapeutics. MarketBeat recorded 1 mentions for Qualigen Therapeutics and 0 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company	Overall Sentiment
Entero Therapeutics	Neutral
Qualigen Therapeutics	Neutral

Entero Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Summary

Qualigen Therapeutics beats Entero Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Qualigen Therapeutics compare to BTC Digital?

Qualigen Therapeutics (NASDAQ:QLGN) and BTC Digital (NASDAQ:BTCT) are both small-cap technology companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-202.16%
BTC Digital	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BTC Digital	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Qualigen Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, BTC Digital has a beta of 5.5, suggesting that its share price is 450% more volatile than the broader market.

In the previous week, BTC Digital had 5 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 6 mentions for BTC Digital and 1 mentions for Qualigen Therapeutics. BTC Digital's average media sentiment score of 0.24 beat Qualigen Therapeutics' score of 0.00 indicating that BTC Digital is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qualigen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BTC Digital	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 7.3% of BTC Digital shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 0.2% of BTC Digital shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Qualigen Therapeutics has higher earnings, but lower revenue than BTC Digital. BTC Digital is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A
BTC Digital	$14.04M	0.77	-$9.06M	-$1.20	N/A

Summary

BTC Digital beats Qualigen Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Cloudastructure?

Qualigen Therapeutics (NASDAQ:QLGN) and Cloudastructure (NASDAQ:CSAI) are both small-cap technology companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

3.2% of Qualigen Therapeutics shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 21.8% of Cloudastructure shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Qualigen Therapeutics has a net margin of 0.00% compared to Cloudastructure's net margin of -145.25%. Qualigen Therapeutics' return on equity of 0.00% beat Cloudastructure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-202.16%
Cloudastructure	-145.25%	-167.05%	-103.30%

Qualigen Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Cloudastructure has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

In the previous week, Cloudastructure had 2 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 3 mentions for Cloudastructure and 1 mentions for Qualigen Therapeutics. Cloudastructure's average media sentiment score of 0.92 beat Qualigen Therapeutics' score of 0.00 indicating that Cloudastructure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qualigen Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cloudastructure	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qualigen Therapeutics has higher earnings, but lower revenue than Cloudastructure. Cloudastructure is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A
Cloudastructure	$5.07M	0.91	-$8.46M	-$14.33	N/A

Cloudastructure has a consensus target price of $45.00, indicating a potential upside of 750.66%. Given Cloudastructure's stronger consensus rating and higher probable upside, analysts clearly believe Cloudastructure is more favorable than Qualigen Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cloudastructure	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cloudastructure beats Qualigen Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Qualigen Therapeutics compare to HeartCore Enterprises?

HeartCore Enterprises (NASDAQ:HTCR) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartCore Enterprises	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

HeartCore Enterprises has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

In the previous week, Qualigen Therapeutics had 1 more articles in the media than HeartCore Enterprises. MarketBeat recorded 1 mentions for Qualigen Therapeutics and 0 mentions for HeartCore Enterprises. HeartCore Enterprises' average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company	Overall Sentiment
HeartCore Enterprises	Neutral
Qualigen Therapeutics	Neutral

1.7% of HeartCore Enterprises shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 57.4% of HeartCore Enterprises shares are owned by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

HeartCore Enterprises has a net margin of 15.42% compared to Qualigen Therapeutics' net margin of 0.00%. Qualigen Therapeutics' return on equity of 0.00% beat HeartCore Enterprises' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HeartCore Enterprises	15.42%	-138.90%	-53.97%
Qualigen Therapeutics	N/A	N/A	-202.16%

HeartCore Enterprises has higher revenue and earnings than Qualigen Therapeutics. HeartCore Enterprises is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HeartCore Enterprises	$8.97M	0.45	$5.79M	-$4.21	N/A
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A

Summary

HeartCore Enterprises beats Qualigen Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Avalon GloboCare?

Avalon GloboCare (NASDAQ:ALBT) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap technology companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Avalon GloboCare has a beta of -0.03, indicating that its stock price is 103% less volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

In the previous week, Qualigen Therapeutics had 1 more articles in the media than Avalon GloboCare. MarketBeat recorded 1 mentions for Qualigen Therapeutics and 0 mentions for Avalon GloboCare. Avalon GloboCare's average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company	Overall Sentiment
Avalon GloboCare	Neutral
Qualigen Therapeutics	Neutral

Qualigen Therapeutics has lower revenue, but higher earnings than Avalon GloboCare. Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalon GloboCare	$1.26M	3.22	-$18.26M	-$3.51	N/A
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.4% of Avalon GloboCare shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 24.2% of Avalon GloboCare shares are held by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	N/A	N/A	-74.36%
Qualigen Therapeutics	N/A	N/A	-202.16%

Summary

Avalon GloboCare beats Qualigen Therapeutics on 5 of the 9 factors compared between the two stocks.

Get Qualigen Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QLGN vs. The Competition

Export

Metric	Qualigen Therapeutics	Software Industry	Technology Sector	NASDAQ Exchange
Market Cap	$1.90M	$15.67B	$29.55B	$12.85B
Dividend Yield	N/A	3.42%	2.75%	11.08%
P/E Ratio	-0.15	127.26	73.35	24.25
Price / Sales	N/A	1,303.80	598.97	101.53
Price / Cash	N/A	48.13	50.35	53.99
Price / Book	-0.27	7.50	9.44	6.20
Net Income	-$6.26M	$434.60M	$679.74M	$348.59M
7 Day Performance	65.41%	1.62%	-1.29%	0.08%
1 Month Performance	40.18%	7.50%	4.03%	3.88%
1 Year Performance	-39.78%	5.00%	189.70%	16.98%

Qualigen Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QLGN Qualigen Therapeutics	0.0054 of 5 stars	$1.12 -4.7%	N/A	-39.8%	$1.90M	N/A	N/A	50	Gap Up
ENTO Entero Therapeutics	N/A	$3.15 +4.7%	N/A	+75.0%	$5.00M	N/A	N/A	9
BTCT BTC Digital	0.5296 of 5 stars	$0.47 -6.9%	N/A	-57.5%	$4.76M	$14.04M	N/A	16	News Coverage
CSAI Cloudastructure	2.9521 of 5 stars	$5.19 -2.8%	$45.00 +767.1%	-88.8%	$4.44M	$5.07M	N/A	20	Earnings Report
HTCR HeartCore Enterprises	1.0162 of 5 stars	$2.69 -7.2%	N/A	-81.8%	$4.18M	$8.12M	N/A	40	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QLGN) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Qualigen Therapeutics (QLGN) Competitors

QLGN vs. ENTO, BTCT, CSAI, HTCR, and ALBT

How does Qualigen Therapeutics compare to Entero Therapeutics?

Summary

How does Qualigen Therapeutics compare to BTC Digital?

Summary

How does Qualigen Therapeutics compare to Cloudastructure?

Summary

How does Qualigen Therapeutics compare to HeartCore Enterprises?

Summary

How does Qualigen Therapeutics compare to Avalon GloboCare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QLGN vs. The Competition

Qualigen Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Qualigen Therapeutics (QLGN) Competitors

QLGN vs. ENTO, BTCT, CSAI, HTCR, and ALBT

How does Qualigen Therapeutics compare to Entero Therapeutics?

Do analysts rate ENTO or QLGN?

Is ENTO or QLGN more profitable?

Do institutionals and insiders hold more shares of ENTO or QLGN?

Which has higher earnings & valuation, ENTO or QLGN?

Does the media favor ENTO or QLGN?

Which has more volatility & risk, ENTO or QLGN?

Summary

How does Qualigen Therapeutics compare to BTC Digital?

Is QLGN or BTCT more profitable?

Do analysts recommend QLGN or BTCT?

Which has more risk & volatility, QLGN or BTCT?

Does the media refer more to QLGN or BTCT?

Do institutionals & insiders have more ownership in QLGN or BTCT?

Which has stronger earnings and valuation, QLGN or BTCT?

Summary

How does Qualigen Therapeutics compare to Cloudastructure?

Do institutionals and insiders have more ownership in QLGN or CSAI?

Is QLGN or CSAI more profitable?

Which has more risk and volatility, QLGN or CSAI?

Does the media prefer QLGN or CSAI?

Which has better valuation and earnings, QLGN or CSAI?

Do analysts recommend QLGN or CSAI?

Summary

How does Qualigen Therapeutics compare to HeartCore Enterprises?

Do analysts rate HTCR or QLGN?

Which has more volatility & risk, HTCR or QLGN?

Does the media refer more to HTCR or QLGN?

Do institutionals & insiders have more ownership in HTCR or QLGN?

Is HTCR or QLGN more profitable?

Which has higher earnings and valuation, HTCR or QLGN?

Summary

How does Qualigen Therapeutics compare to Avalon GloboCare?

Which has more risk and volatility, ALBT or QLGN?

Does the media favor ALBT or QLGN?

Which has stronger earnings & valuation, ALBT or QLGN?

Do analysts rate ALBT or QLGN?

Do insiders & institutionals hold more shares of ALBT or QLGN?

Is ALBT or QLGN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QLGN vs. The Competition

Qualigen Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools